$406 Million is the total value of Logos Global Management LP's 40 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | New | MIRATI THERAPEUTICS INC | $32,687,000 | – | 253,660 | +100.0% | 8.06% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $29,163,000 | – | 226,002 | +100.0% | 7.19% | – |
| MRTX | New | MIRATI THERAPEUTICS INCput | $27,061,000 | – | 210,000 | +100.0% | 6.67% | – |
| MRTX | New | MIRATI THERAPEUTICS INCcall | $25,772,000 | – | 200,000 | +100.0% | 6.35% | – |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $25,027,000 | – | 179,898 | +100.0% | 6.17% | – |
| AMRN | New | AMARIN CORP PLCspons adr new | $20,637,000 | – | 962,553 | +100.0% | 5.09% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $17,977,000 | – | 587,108 | +100.0% | 4.43% | – |
| BLUE | New | BLUEBIRD BIO INC | $17,938,000 | – | 204,420 | +100.0% | 4.42% | – |
| ZYME | New | ZYMEWORKS INC | $17,691,000 | – | 389,153 | +100.0% | 4.36% | – |
| MYOK | New | MYOKARDIA INC | $16,837,000 | – | 231,009 | +100.0% | 4.15% | – |
| ZGNX | New | ZOGENIX INC | $14,963,000 | – | 287,024 | +100.0% | 3.69% | – |
| XLRN | New | ACCELERON PHARMA INC | $14,192,000 | – | 267,676 | +100.0% | 3.50% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $13,727,000 | – | 190,150 | +100.0% | 3.38% | – |
| AXSM | New | AXSOME THERAPEUTICS INC | $12,913,000 | – | 124,937 | +100.0% | 3.18% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $11,387,000 | – | 55,700 | +100.0% | 2.81% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $10,193,000 | – | 187,242 | +100.0% | 2.51% | – |
| BMYRT | New | BRISTOL MYERS SQUIBB COright 99/99/9999 | $10,002,000 | – | 3,322,816 | +100.0% | 2.47% | – |
| QURE | New | UNIQURE NV | $9,920,000 | – | 138,425 | +100.0% | 2.44% | – |
| CCXI | New | CHEMOCENTRYX INC | $7,366,000 | – | 186,238 | +100.0% | 1.82% | – |
| KDMN | New | KADMON HLDGS INC | $6,117,000 | – | 1,350,351 | +100.0% | 1.51% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $6,105,000 | – | 220,543 | +100.0% | 1.50% | – |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $5,173,000 | – | 134,397 | +100.0% | 1.28% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $5,083,000 | – | 223,337 | +100.0% | 1.25% | – |
| CNST | New | CONSTELLATION PHARMCETICLS I | $4,760,000 | – | 101,050 | +100.0% | 1.17% | – |
| MTEM | New | MOLECULAR TEMPLATES INC | $4,754,000 | – | 339,900 | +100.0% | 1.17% | – |
| ISEE | New | IVERIC BIO INC | $4,491,000 | – | 523,462 | +100.0% | 1.11% | – |
| IGMS | New | IGM BIOSCIENCES INC | $4,366,000 | – | 114,411 | +100.0% | 1.08% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $3,846,000 | – | 188,000 | +100.0% | 0.95% | – |
| BLU | New | BELLUS HEALTH INC NEW | $3,227,000 | – | 424,618 | +100.0% | 0.80% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $2,987,000 | – | 39,647 | +100.0% | 0.74% | – |
| New | APTOSE BIOSCIENCES INC | $2,970,000 | – | 523,803 | +100.0% | 0.73% | – | |
| MEIP | New | MEI PHARMA INC | $2,841,000 | – | 1,145,528 | +100.0% | 0.70% | – |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $2,485,000 | – | 27,279 | +100.0% | 0.61% | – |
| SVRA | New | SAVARA INC | $2,476,000 | – | 613,999 | +100.0% | 0.61% | – |
| ETNB | New | 89BIO INC | $2,276,000 | – | 86,591 | +100.0% | 0.56% | – |
| FULC | New | FULCRUM THERAPEUTICS INC | $2,057,000 | – | 123,635 | +100.0% | 0.51% | – |
| NERV | New | MINERVA NEUROSCIENCES INC | $1,620,000 | – | 227,835 | +100.0% | 0.40% | – |
| ARDX | New | ARDELYX INC | $1,594,000 | – | 212,449 | +100.0% | 0.39% | – |
| NLTX | New | NEOLEUKIN THERAPEUTICS INC | $499,000 | – | 40,529 | +100.0% | 0.12% | – |
| KZR | New | KEZAR LIFE SCIENCES INC | $493,000 | – | 122,931 | +100.0% | 0.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.